Medivation, Inc. (NASDAQ:MDVN)

CAPS Rating: 3 out of 5

A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies.

Results 1 - 20 of 33 : 1 2 Next »

Recs

0
Member Avatar asilverp (27.08) Submitted: 8/26/2014 8:04:33 PM : Underperform Start Price: $88.60 MDVN Score: -13.93

At a stock price of 47 times book value, an unprofitable business and 162 dollars of debt for every dollar of equity what could possibly go wrong?

Recs

1
Member Avatar SkepBioInvestor (95.91) Submitted: 5/13/2014 5:00:37 PM : Outperform Start Price: $66.01 MDVN Score: +46.94

buyout candidate

Recs

1
Member Avatar baileysmom (< 20) Submitted: 1/26/2014 8:08:50 PM : Outperform Start Price: $77.65 MDVN Score: +18.03

Prostate cancer is not going away anytime soon and this drug is making a positive impact on patients. Easier to take 4 pills in the morning than sit in an infusion center for 3 hours. Also doesn't require Prednisone which is a plus over its rival J & J's Zytiga.

Recs

1
Member Avatar 1russianguy (70.31) Submitted: 10/9/2013 2:16:47 PM : Outperform Start Price: $50.51 MDVN Score: +78.28

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

1
Member Avatar 1picks (87.21) Submitted: 10/7/2013 11:15:22 AM : Outperform Start Price: $57.17 MDVN Score: +57.81

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

1
Member Avatar TMFEBCapital (23.22) Submitted: 9/20/2013 7:25:31 AM : Outperform Start Price: $60.10 MDVN Score: +51.24

MDVN's Xtandi has data coming for a pre-chemo prostate cancer indication and as a potential first line treatment for Xtandi too. Positive data from those trials would expand the patient pool and could significantly grow sales.

Recs

0
Member Avatar scotttu34 (< 20) Submitted: 6/17/2013 4:48:56 PM : Outperform Start Price: $47.58 MDVN Score: +89.49

Not much competition from other drug makers for their prostate cancer drug for probably a year or so.

Recs

0
Member Avatar genedom (97.85) Submitted: 2/3/2013 2:45:26 PM : Outperform Start Price: $56.65 MDVN Score: +44.54

Momentum

Recs

0
Member Avatar GirlsUnder30 (95.34) Submitted: 12/27/2012 9:32:23 AM : Underperform Start Price: $51.37 MDVN Score: -58.60

This drug company doesn't appear to have anything in its portfolio to warrant this valuation.

Recs

1
Member Avatar HIGHG33K (89.17) Submitted: 7/9/2012 3:33:54 PM : Outperform Start Price: $47.94 MDVN Score: +61.75

Will rule in prostate cancer field.

Recs

0
Member Avatar GoodTrader1 (< 20) Submitted: 6/6/2012 4:38:42 PM : Outperform Start Price: $43.94 MDVN Score: +78.91

high relative strenght

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 3/12/2012 2:51:09 PM : Outperform Start Price: $36.44 MDVN Score: +129.99

went up 237% for portefeille.

Recs

1
Member Avatar lszachary (< 20) Submitted: 3/6/2012 9:26:53 PM : Outperform Start Price: $32.06 MDVN Score: +164.82

new prostate drug

Recs

0
Member Avatar HoldThatWinner (30.97) Submitted: 2/28/2012 9:05:53 PM : Underperform Start Price: $33.50 MDVN Score: -153.68

Another overinflated biotech that hasn't proven anything as of yet.

Recs

1
Member Avatar Olddognwtrx (< 20) Submitted: 11/20/2011 10:02:14 AM : Outperform Start Price: $20.75 MDVN Score: +316.42

MDV3100 looks as if it might take much of the prostate cancer market and work in breast cancer also. Sales of 2 billion on the low side. Someone will buy them after the launch. 100+ by the end of 2012. Buy on any dips and add slowly.

Recs

0
Member Avatar PharmaD (93.43) Submitted: 10/26/2011 11:11:58 PM : Outperform Start Price: $8.73 MDVN Score: +988.63

Phase 3 data coming soon..... And will likely be great

Recs

4
Member Avatar zzlangerhans (99.83) Submitted: 8/25/2011 12:28:39 PM : Outperform Start Price: $7.45 MDVN Score: +1,169.53

Hopefully Dimebon has now provided enough failures to reduce its contribution to Medivation's enterprise value to zero. The new central story is the promising prostate cancer drug MDV3100 . In June the company reported preliminary data from an MD Anderson study of MDV3100 showing that 45% of 55 advanced prostate ca patients experienced at least a 50% decrease in PSA levels. An interim analysis of the AFFIRM phase III placebo controlled trial of MDV3100 in castration-resistant prostate cancer may be performed before the end of the year. The share price hasn't seen 15 since February, when encouraging data for MDV3100 first started to get noticed.

Recs

1
Member Avatar KurtEng (31.18) Submitted: 8/17/2011 4:22:41 PM : Underperform Start Price: $7.84 MDVN Score: -1,103.73

I would never put my own money into this stock. They will have to grow like crazy to justify the current price and so far they haven't generated any positive cash flow. The downside seems huge.

Recs

1
Member Avatar musclemilk13 (99.44) Submitted: 4/26/2010 3:24:01 PM : Outperform Start Price: $5.69 MDVN Score: +1,592.28

copying andrelikesMTL

Recs

0
Member Avatar Pollywol (< 20) Submitted: 3/6/2010 5:31:31 AM : Outperform Start Price: $6.55 MDVN Score: +1,348.62

The drug may not be completely dead yet, says University of Southern California Alzheimer's expert Lon Schneider.

Results 1 - 20 of 33 : 1 2 Next »

Featured Broker Partners


Advertisement